



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/073,596	05/06/1998	RALPH M. STEINMAN	20164000US5	9977
43852	7590	02/06/2008		
MERIX BIOSCIENCE, INC. 4233 TECHNOLOGY DRIVE DURHAM, NC 27704			EXAMINER EWOLDT, GERALD R	
			ART UNIT 1644	PAPER NUMBER
			MAIL DATE 02/06/2008	DELIVERY MODE PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 09/073,596	<b>Applicant(s)</b> STEINMAN ET AL.	
	<b>Examiner</b> G. R. Ewoldt, Ph.D.	<b>Art Unit</b> 1644	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 04 December 2007.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 89,91,92,94,95,99,101,103-113,115-121 and 140-144 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 89,91,92,94,95,99,101,103-113,115-121 and 140-144 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

**DETAILED ACTION**

1. Applicant's amendments and remarks filed 11/29/07 are acknowledged.
2. Claims 89, 91, 92, 94, 95, 99, 101, 103-113, 115-121, 140-144 are pending.
3. In view of Applicant's amendments the previous rejection under 35 U.S.C. § 112, first paragraph has been withdrawn.
4. The instant application is a continuation in part of U.S. Application Nos. 07/981,357, filed 11/25/1992, and 07/861,612, filed 4/01/92. However, the applications do not disclose the invention of the instant claims. First note that the method step employed in instant Claim 101 comprising, "treating the tissue source comprising dendritic cell precursors to increase the proportion of dendritic cell precursors", is not found in the '612 application. Further, neither the '612 nor the '357 applications disclose the cells being cultured with an antigen as is recited in the last step of Claims 101 and 120. Finally, neither application discloses a microorganism antigen, in particular a BCG antigen. Accordingly, the benefit of priority to said applications is denied. The priority date of the instant application is the filing date of parent application 08/040,677 which is 3/31/1993.
5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -  
(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
6. Claims 89, 91, 92, 94, 95, 99, 101, 103-113, 115-121, 140-144 stand/are rejected under 35 U.S.C. 102(a) as being anticipated by Pancholi et al. (1992).

As set forth previously, Pancholi et al. teaches a pharmaceutical composition comprising human dendritic cells (DCs) pulsed with tuberculosis antigens (see particularly page 218, last paragraph).

The reference clearly anticipates the claimed invention.

Regarding product-by-process claims, MPEP 2113 states:

"[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process." *In re Thorpe*, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985), and

"The Patent Office bears a lesser burden of proof in making out a case of *prima facie* obviousness for product-by-process claims because of their peculiar nature" than when a product is claimed in the conventional fashion. *In re Fessmann*, 489 F.2d 742, 744, 180 USPQ 324, 326 (CCPA 1974). Once the examiner provides a rationale tending to show that the claimed product appears to be the same or similar to that of the prior art, although produced by a different process, the burden shifts to applicant to come forward with evidence establishing an unobvious difference between the claimed product and the prior art product. *In re Marosi*, 710 F.2d 798, 802, 218 USPQ 289, 292 (Fed. Cir.1983).

Applicant's arguments, filed 11/29/07, have been fully considered but are not found persuasive. Applicant again argues that Pancholi et al. is not available as art.

The issue of priority has been addressed in Section 4 above.

Applicant again argues that the DCs of the reference are not the DCs of the claims.

As set forth previously, the mouse DCs of the instant specification cannot be compared to the human DCs of the reference. Further, the experimental methods of the reference are different than are those of the instant specification, e.g., different populations of T cells are employed. Accordingly, no meaningful comparison can be made.

7. The following are new grounds for rejection.

8. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

9. Claims 101, 103-113, 115, 116, 118-121, 140, and 141 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by

Steinman et al. (1974, IDS) as evidenced by O'Doherty et al. (1994, IDS).


Steinman et al. teaches an *in vitro* composition comprising a mature DC (see particularly Materials and Methods). O'Doherty et al. is merely cited to show that the spleen and lymph node preparations of the reference would have included CD11<sup>+</sup> mature DCs (see particularly page 492, column 2, last paragraph). As set forth above, the patentability of a product does not depend on its method of production.

The reference clearly anticipates the claimed invention.

10. No claim is allowed.

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (571) 272-0843. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Eileen O'Hara, Ph.D. can be reached on (571) 272-0878.

12. **Please Note:** Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197.

  
2/1/03

G.R. Ewoldt, Ph.D.  
Primary Examiner  
Technology Center 1600